In contrast, the combination of rapamycin with gemcitabine-cisplatin did not show improved efficacy in treating muscle-invasive bladder cancer, as evidenced by a relatively low complete response rate of 23%, despite the inhibition of mTOR in tumor cells (51). The gene discussed is MTOR; the disease is neoplasm.